None listed
Conditions
Brief summary
The reduction in quality of life and illness burden experienced by people with end stage kidney disease (ESKD) is exacerbated by the condition of ‘uraemic neuropathy’. Uraemic neuropathy affects between 60 and 100% of people with ESKD and can lead to loss of function as well as discomfort or pain. It is progressive with no specific cures or methods of retarding progression other than transplantation. The FINESSE study will compare the effect of haemodiafiltration and standard haemodialysis with high-flux membranes on the development and progression of uraemic neuropathy.
Interventions
Haemodiafiltration
Haemodiafiltration differs from conventional haemodialysis in employing convection as well as diffusion principles to remove solutes and excess water.
Participants will receive their routine haemodialysis hours and sessions (as prescribed by their treating nephrologist) with haemodiafiltration.
Sponsors
Statewide Renal Services
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Incident or prevalent patients requiring maintenance haemodialysis therapy for end stage kidney disease. 2. Aged 18 years or older 3. Suitable for either haemodiafiltration or standard dialysis in the view of the treating physician 4. Agreeable to randomisation
Exclusion criteria
Patients will be excluded if, in the opinion or knowledge of the responsible clinician: 1. Life expectancy is less than 6 months. 2. Definite plans to undergo renal transplantation, transfer to a non-study site, transfer to peritoneal dialysis or transfer to home haemodialysis within 12 months of entry to the study. 3. Unable or unwilling to complete neuropathy staging, including nerve conduction studies. 4. Receiving haemodiafiltration
Outcome results
None listed